This picture taken on May 23, 2020 shows a laboratory technician holding a dose of a COVID-19 novel coronavirus vaccine candidate ready for trial on monkeys at the National Primate Research Center of Thailand at Chulalongkorn University in Saraburi. (Mladen Antonov/AFP/Getty Images/TNS)

This picture taken on May 23, 2020 shows a laboratory technician holding a dose of a COVID-19 novel coronavirus vaccine candidate ready for trial on monkeys at the National Primate Research Center of Thailand at Chulalongkorn University in Saraburi. (Mladen Antonov/AFP/Getty Images/TNS)

A look at promising and overhyped COVID therapies after a tumultuous year of research

Here’s a look at some of the drugs – deemed effective and not – that made headlines in recent months

Alongside the headline-grabbing race for a COVID-19 vaccine, the hunt for effective treatments has unfolded with its own share of flameouts and triumphs.

Thanks to large randomized trials in the United Kingdom and elsewhere, administering steroids to patients with moderate or severe illness has become part of standard care, but clinicians say few other tools have emerged.

The best known COVID-19 drug is likely dexamethasone, a corticosteroid with anti-inflammatory and immunosuppressant effects for hospitalized patients who need help breathing.

But while that drug is credited with helping efforts to bring down hospital mortality rates, credit also goes to discoveries about what does not work against the novel coronavirus – thereby ensuring people get appropriate care.

Here’s a look at some of the drugs – deemed effective and not – that made headlines in recent months for fostering hype and hope:

Health-Canada approved

Remdesivir – Sold under the name Veklury, this Gilead Sciences drug was among various treatments given to former U.S. President Donald Trump when he successfully overcame COVID-19 last year. But its ability to cut deaths has since been largely discounted by a World Health Organization trial. An earlier study by Gilead found the drug helped moderately ill patients recover more quickly if given for five days, but that benefit was less clear if given over 10 days.

Health Canada noted clinical trial data was limited when it approved remdesivir for COVID-19 last July but said “given the high unmet medical need and emergency context of the COVID-19 pandemic, Health Canada considered the balance of benefit and harm for Veklury to be positive.”

Bamlanivimab – The federal government paid US$32.5 million for 26,000 doses of this monoclonal antibody that targets the spike protein of SARS-CoV-2. Eli Lilly says an intravenous infusion can ease and prevent COVID-19 symptoms among mild-to-moderate cases in high-risk groups including seniors.

Nevertheless, it has yet to be embraced by clinicians, with Hamilton infectious disease physician Zain Chagla calling it “a good example of a drug that might work on paper but really isn’t a great drug to invest in.”

The associate professor of medicine at McMaster University points to barriers to implementation, which include the staffing and time required to implement the transfusion.

Alberta Health Services says it’s considering a trial to determine “potential for benefit and feasibility of use” while British Columbia said Monday a clinical trial in Surrey would be funded by AbCellera, the Vancouver company which helped discover bamlanivimab.

Cautions against early hype

Hydroxychloroquine – Commonly used to treat lupus and rheumatoid arthritis, this drug earned infamy when U.S. President Donald Trump touted its efficacy with COVID-19 before the science was in. Since then, multiple rigorous trials have concluded it offers no benefit to preventing or treating illness while underscoring the dangers of mixing politics and science.

Colchicine –Just last week, the Quebec government cautioned clinicians against embracing this anti-inflammatory as a COVID-19 therapy after the Montreal Heart Institute touted the common gout medication as “a major scientific discovery.” Scientists at the National Institute for Excellence in Health and Social Services acknowledged the institute’s study showed positive results, but said the benefit was too small.

Other contenders

Tocilizumab –Dr. Niall Ferguson, head of critical care at the University Health Network and Sinai Health System, sees potential in early data for tocilizumab, approved for use in Canada to treat rheumatoid arthritis. Although evolving data has been mixed and is still emerging, Ferguson notes the monoclonal antibody is already being used off-label for some severe patients.

Heparin – Canadian scientists involved in a global trial for this blood thinner say interim data suggests it can keep some moderately ill COVID-19 patients from deteriorating further. University Health Network scientist Ewan Goligher says the probability of requiring life support dropped by about a third among subjects. He expects the study’s findings to be released soon.

Peginterferon-lambda – Research into this prospective antiviral treatment was recently published in Lancet Respiratory Medicine. Lead researcher Dr. Jordan Feld, a liver specialist at UHN’s Toronto Centre for Liver Disease, says a small Phase 2 trial found it significantly sped recovery for outpatients. Although more research is needed, he suspected it could offer an important way to quickly bring down the virus level in infected patients and reduce their risk of spreading disease to others.

Cassandra Szklarski, The Canadian Press

Like us on Facebook and follow us on Twitter.

Want to support local journalism? Make a donation here.

Coronavirus

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Interior Health nurses were administering COVID-19 vaccines to seniors and care aides in Kelowna on Tuesday, March 16. (Phil McLachlan/Capital News)
Kelowna martial arts gym refusing patrons who have been vaccinated, wear masks

Interior Health previously issued a ticket to Flow Academy in February for non-compliance with public health orders

Forward Elan Bar Lev Wise of the West Kelowna Warriors (right, shown playing for the Vernon Vipers in 2019) has been suspended nine games by the B.C. Hockey League for being the instigator and aggressor in an after-the-game fight with Vernon’s Kjell Kjemhus Monday, April 12, at Kal Tire Place. Kjemhus was given a two-game suspension for his role in the fight after the game was over. (Morning Star - file photo)
West Kelowna Warriors forward handed lengthy suspension

Elan Bar Lev Wise fought Vernon Vipers forward Kjell Kjemhus after BCHL game was over Monday, April 12; Kjemhus suspended two games

A worker is seen dismantling the damaged crane on April 13. (Aaron Hemens - Kelowna Capital News)
Crews dismantle crane damaged in Glenmore Construction fire

The crane expected to be removed by the end of the day

The Okanagan Forest Task Force’s only means of getting garbage out of the backcountry broke down on Tuesday, April 6. (Kane Blake - Okanagan Forest Task Force)
Okanagan forest cleanup group’s truck repaired free of charge

Okanagan Forest Task Force uses the truck to haul garbage out of the backcountry

Lime e-scooters will soon be offered in Kelowna. (Photo: Kris Krug)
E-scooters now allowed on Kelowna roadways under provincial pilot program

‘Rather than a novelty, this change will enable e-scooters to be used for more utilitarian transportation purposes’

Burnaby MLA Raj Chouhan presides as Speaker of the B.C. legislature, which opened it spring session April 12 with a speech from the throne. THE CANADIAN PRESS
B.C. NDP promises more health care spending, business support in 2021 budget

John Horgan government to ‘carefully return to balanced budgets’

A shop up on Grand Oro Road near Twin Lakes burned down on Monday. (Facebook)
Fire rips through shop in small South Okanagan town

The building was destroyed despite community efforts to fight the fire

WATCH: Conservation group releases short doc on saving South Okanagan’s ‘precious’ Sickle Point

Sickle Point, the last intact wetland near Skaha Lake, is facing the prospect of development

Protesters occupied a road leading to Fairy Creek Watershed near Port Renfrew. (Submitted photo)
B.C. First Nation says logging activist interference not welcome at Fairy Creek

Vancouver Island’s Pacheedaht concerned about increasing polarization over forestry activities

Skaha Lake Middle School. (File photo)
COVID exposure at Penticton middle school

Skaha Middle School is the latest in growing lists of exposure in the Okanagan

A five-storey, 60-unit building has been proposed for 8709 Jubilee Rd. E., Summerland. The proposal will be the subject of a public hearing on March 22. (Image by GTA Architecture)
Zoning, OCP amendments adopted for Summerland housing development

Additional variances will be needed for controversial five-storey, 60-unit housing development

Cannabis bought in British Columbia (Ashley Wadhwani/Black Press Media)
Is it time to start thinking about greener ways to package cannabis?

Packaging suppliers are still figuring eco-friendly and affordable packaging options that fit the mandates of Cannabis Regulations

Guinevere, lovingly referred to by Jackee Sullivan and her family as Gwenny, is in need of a gynecological surgery. The family is raising money to help offset the cost of the procedure. (Jackee Sullivan/Special to Langley Advance Times)
Langley lizard’s owners raise funds for gynecological surgery

The young reptile is scheduled for operation on Tuesday

Facebook screenshot of the sea lion on Holberg Road. (Greg Clarke Facebook video)
VIDEO: Sea lion randomly spotted on remote B.C. logging road

Greg Clarke was driving home on the Holberg Road April 12, when he saw a large sea lion.

Most Read